,i #aahth ,,congress #ast ,session ,h4 ,r4 #eege ,,in ,,the ,,house ,,of ,,representatives ,september #ai1 #bjbc,mr4 ,posey introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committees on ,armed ,services1 ,veterans' ,affairs1 and ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to direct the ,secretaries of ,health and ,human ,services1 ,defense1 and ,veterans ,affairs to end ,american over-dependence on ,chinese pharmaceuticals by encouraging the growth of a robust domestic medicine supply chain for generic drugs1 to empower the ,food and ,drug ,administration to issue boxed warnings in the case of critical contamination1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,safe ,medicine ,act4 #b4 ,findings ,congress finds the following3 7#a7 ,following the enactment of the ,drug ,price ,competition and ,patent ,term ,restoration ,act of #aihd 7,public ,law #ih-dag71 the ,people's ,republic of ,china was able to corner the market on generic drugs1 pharmaceutical ingredients1 and related materials through its steady supply of readily exploitable labor and threadbare safety regulations4 ,ninety percent of the medications taken by individuals in the ,united ,states are generic1 rendering them especially dependent on supplies originating in the ,people's ,republic of ,china4 7#b7 ,the number of drugs produced outside of the ,united ,states doubled between #bjja and #bjjh4 ,at present1 #hj percent of the active pharmaceutical ingredients used in drugs taken by individuals in the ,united ,states come from overseas1 mainly the ,people's ,republic of ,china and the ,republic of ,india4 ,the ,united ,states no longer produces penicillin1 with the last fermentation plant phasing out of production in #bjjd4 7#c7 ,in #bjjh1 the counterfeiting of ,heparin precursor chemicals by a ,chinese-based pharmaceutical plant led to the deaths of #ha individuals in the ,united ,states1 with #ghe more being severely injured4 ,the counterfeit product cost one-hundredth of the price of the real product1 indicating a clear economic motive for distributing contaminated materials4 7#d7 ,in #bjah1 the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 issued recalls of ,valsartan1 ,losartan1 and ,irbesartan1 common blood pressure drugs4 ,the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 determined that versions of such drugs have been contaminated as a result of ,chinese and ,indian manufacturing practices and that one ,chinese company1 ,zhejaiang ,huahai ,pharmaceuticals1 had systemic problems of supervision1 with the potent carcinogens ,n-,nitroso-,n-methyl-#d-;aminobutyric acid 7,,nmba71 ,n-,nitrosodimethylamine 7,,ndma71 and ,n-,nitrosodiethylamine 7,,ndea71 for a period of #d years before being detected4 7#e7 ,during an ,october #cj1 #bjbj1 hearing before the ,health ,subcommittee of the ,energy and ,commerce ,committee of the ,house of ,representatives1 it was discovered that the ,food and ,drug ,administration 7,,fda7 has data on active pharmaceutical ingredient facilities and locations because they regulate and inspect them4 ,but the ,,fda does not know how much volume is produced at these facilities4 ,a single plant could make #ij percent of global supply or #aj percent1 but the ,,fda does not know4 7#f7 ,the ,,fda cannot determine the ,united ,states dependence because it does not thoroughly regulate or inspect the facilities where the key chemicals and raw materials to make active pharmaceutical ingredients are made4 7#g7 ,domestic pharmaceutical facilities undergo far more rigorous inspections than manufacturing facilities in the ,people's ,republic of ,china4 ,since early #bjbj1 the ,,fda recalled its inspectors from ,china and elsewhere to protect them from the ,coronavirus4 ,as a result1 ,,fda inspections have plummeted to near zero for the past year4 7#h7 ,in #bjaj1 the ,people's ,republic of ,china embargoed the shipment of rare earth metals to ,japan as political leverage in its negotiations over a boating incident that took place between the #b countries in the ,east ,china ,sea4 ,national security experts warn that if such an incident were to take place between the ,united ,states and ,china1 and ,china were to embargo medicine and pharmaceutical ingredients1 the ,united ,states would be helpless4 ,sun ,yu and ,demetri ,sevastopulo1 ,china ,targets ,rare ,earth ,export ,curbs ,to ,hobble ,,us ,defense ,industry4 ,ars ,technica1 ,february #af1 #bjba1 arstechnica4com_/tech-policy_/#bjba_/jb_ /;china-targets-rare-earth-export-curbs- to-hobble-us-defense-industry_/4 ,united ,states dependence on ,chinese medicine and pharmaceutical ingredients poses a national security risk4 7#i7 ,the ,united ,states is dependent on other nations1 particularly ,china1 for our generic medicine and key ingredients that are used to make these drugs4 ,inspections at ,chinese facilities are inadequate compared to inspections at facilities located in the ,united ,states4 7#aj7 ,the ,united ,states cannot rely on questionable inspections at facilities located in ,china4 7#aa7 ,to protect ,americans1 we must encourage the development of essential generic drug manufacturing here in the ,united ,states and countries allied with the ,united ,states in a current defense effort for the #bbg essential medicines and medical countermeasures identified by the ,,fda in accordance with ,executive ,order #acidd1 issued on ,august #f1 #bjbj4 #c4 ,domestic manufacturing to end over-dependence of the ,united ,states on ,chinese drugs 7a7 ,in general ,the ,secretaries of ,health and ,human ,services1 ,defense1 and ,veterans ,affairs1 acting jointly and in consultation with the ,commissioner of ,food and ,drugs1 shall-- 7#a7 not later than #ahj days after the date of enactment of this ,act1 develop a procurement strategy1 including for long-term contracts1 to strengthen and mobilize the ,public ,health ,industrial ,base to increase the manufacture in the ,united ,states of essential medicines1 medical countermeasures1 and critical inputs1 including the #bbg essential medicines1 medical countermeasures1 and critical inputs published on ,october #cj1 #bjbj1 by the ,food and ,drug ,administration in accordance with ,executive ,order #acidd2 and 7#b7 beginning as soon as feasible after the development of such strategy1 and not later than #e years after the development of such strategy1 implement such strategy4 7b7 ,contents ,the strategy under subsection 7a7 shall-- 7#a7 be consistent with all applicable ,federal law2 7#b7 identify essential components1 including key starting materials1 active ingredients1 and critical inputs1 necessary for manufacturing the essential medicines and medical countermeasures published on ,october #cj1 #bjbj1 by the ,food and ,drug ,administration in accordance with ,executive ,order #acidd2 and 7#c7 address the capacity of the supply chain and industrial base to strengthen and mobilize the ,public ,health ,industrial ,base to increase the manufacture in the ,united ,states of essential medicines1 medical countermeasures1 and critical inputs4 7c7 ,definitions ,in this section3 7#a7 ,the term critical inputs means active pharmaceutical ingredients1 active pharmaceutical ingredient starting material1 and other ingredients of drugs and components of medical devices that the ,commissioner of ,food and ,drugs determines to be critical in assessing the safety and effectiveness of essential medicines and medical countermeasures4 7#b7 ,the term essential medicine means medicine-- 7,a7 that is needed to protect the ,american public at all times1 including from outbreaks of emerging infectious diseases1 such as ,,covid-#ai1 as well as chemical1 biological1 radiological1 and nuclear threats2 and 7,b7 of which sufficient and reliable1 long-term domestic production of these products1 mostly generic drugs1 their active pharmaceutical ingredients1 and key starting materials1 is needed to minimize potential shortages by reducing the ,nation's dependence on foreign manufacturers of these products4 7#c7 ,the term medical countermeasure means-- 7,a7 a qualified countermeasure 7as defined in section #cai;,f-#a of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bdg;d-#f;a772 7,b7 a qualified pandemic or epidemic product 7as defined in section #cai;,f-#c of such ,act 7#db ,u4,s4,c4 #bdg;d-#f;d772 7,c7 a security countermeasure 7as defined in section #cai;,f-#b of such ,act 7#db ,u4,s4,c4 #bdg;d-#f;b772 or 7,d7 personal protective equipment 7such as gloves1 respirators 7face masks71 and ventilators74 7#d7 ,the term ,public ,health ,industrial ,base means the facilities and associated workforces within the ,united ,states1 including research and development facilities1 that help produce essential medicines1 medical countermeasures1 and critical inputs for the health care and public health sector4 #d4 ,requiring boxed warnings on potentially contaminated drugs 7a7 ,in general ,the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs1 shall-- 7#a7 issue an order deeming a drug or active pharmaceutical ingredient 7or a category thereof7 to be misbranded within the meaning of section #ejb of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #ceb7 if such drug or active pharmaceutical ingredient 7or category thereof7-- 7,a7 is manufactured in a country that the ,secretary determines may be producing contaminated drugs or active pharmaceutical ingredients because of systemic problems of supervision in the manufacture of drugs or active pharmaceutical ingredients2 and 7,b7 the labeling of such drug or active pharmaceutical ingredient 7or category thereof7 does not bear a boxed warning of the potential for contamination2 7#b7 make each such order effective for a period of not more than #ahj days2 and 7#c7 renew each such order each time the preceding order ends and the criteria listed in paragraph 7#a7 continue to apply4 7b7 ,waivers ,the ,secretary of ,health and ,human ,services1 acting through the ,commissioner of ,food and ,drugs-- 7#a7 may waive the requirement to issue or renew an order under subsection 7a7 so long as the labeling of the drug or active pharmaceutical ingredient 7or category thereof7 bears a boxed warning of the potential for contamination2 7#b7 shall make any such waiver effective for a period not to exceed #ahj days2 and 7#c7 may renew any such waiver one or more times4 #e4 ,limitation on waiver authority under the ,trade ,agreements ,act of #aigi ,section #cja of the ,trade ,agreements ,act of #aigi 7#ai ,u4,s4,c4 #beaa7 is amended by adding at the end the following3 7g7 ,limitation on waiver authority relating to essential medicines1 medical countermeasures1 and critical inputs 7#a7 ,in general ,the authority of the ,president under subsection 7a7 to waive the application of any law1 regulation1 procedure1 or practice regarding ,government procurement does not authorize the waiver of any preferences for goods that are essential medicines1 medical countermeasures1 or critical inputs4 7#b7 ,definitions ,in this subsection1 the terms essential medicines1 medical countermeasures1 and critical inputs-- 7,a7 have the meanings given such terms in section #c7;c7 of the ,safe ,medicine ,act2 and 7,b7 include the #bbg essential medicines1 medical countermeasures1 and critical inputs published on ,october #cj1 #bjbj1 by the ,food and ,drug ,administration in accordance with ,executive ,order #acidd4 4